224 related articles for article (PubMed ID: 20664588)
1. Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma.
Veltman JD; Lambers ME; van Nimwegen M; Hendriks RW; Hoogsteden HC; Hegmans JP; Aerts JG
Br J Cancer; 2010 Aug; 103(5):629-41. PubMed ID: 20664588
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway.
Coscia M; Quaglino E; Iezzi M; Curcio C; Pantaleoni F; Riganti C; Holen I; Mönkkönen H; Boccadoro M; Forni G; Musiani P; Bosia A; Cavallo F; Massaia M
J Cell Mol Med; 2010 Dec; 14(12):2803-15. PubMed ID: 19818098
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts.
Comito G; Pons Segura C; Taddei ML; Lanciotti M; Serni S; Morandi A; Chiarugi P; Giannoni E
Oncotarget; 2017 Jan; 8(1):118-132. PubMed ID: 27223431
[TBL] [Abstract][Full Text] [Related]
4. The effect of zoledronic acid on the function and differentiation of myeloid cells.
Wolf AM; Rumpold H; Tilg H; Gastl G; Gunsilius E; Wolf D
Haematologica; 2006 Sep; 91(9):1165-71. PubMed ID: 16956814
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid prevents the tumor-promoting effects of mesenchymal stem cells via MCP-1 dependent recruitment of macrophages.
Jia XH; Du Y; Mao D; Wang ZL; He ZQ; Qiu JD; Ma XB; Shang WT; Ding D; Tian J
Oncotarget; 2015 Sep; 6(28):26018-28. PubMed ID: 26305552
[TBL] [Abstract][Full Text] [Related]
6. Zoledronic acid inhibits macrophage/microglia-assisted breast cancer cell invasion.
Rietkötter E; Menck K; Bleckmann A; Farhat K; Schaffrinski M; Schulz M; Hanisch UK; Binder C; Pukrop T
Oncotarget; 2013 Sep; 4(9):1449-60. PubMed ID: 24036536
[TBL] [Abstract][Full Text] [Related]
7. Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages.
Tsagozis P; Eriksson F; Pisa P
Cancer Immunol Immunother; 2008 Oct; 57(10):1451-9. PubMed ID: 18297280
[TBL] [Abstract][Full Text] [Related]
8. Direct antitumour activity of zoledronic acid: preclinical and clinical data.
Bosch-Barrera J; Merajver SD; Menéndez JA; Van Poznak C
Clin Transl Oncol; 2011 Mar; 13(3):148-55. PubMed ID: 21421459
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid renders human M1 and M2 macrophages susceptible to Vδ2
Fowler DW; Copier J; Dalgleish AG; Bodman-Smith MD
Cancer Immunol Immunother; 2017 Sep; 66(9):1205-1215. PubMed ID: 28501938
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.
Porembka MR; Mitchem JB; Belt BA; Hsieh CS; Lee HM; Herndon J; Gillanders WE; Linehan DC; Goedegebuure P
Cancer Immunol Immunother; 2012 Sep; 61(9):1373-85. PubMed ID: 22215137
[TBL] [Abstract][Full Text] [Related]
11. Dose-dependent inhibitory effects of zoledronic acid on osteoblast viability and function in vitro.
Huang X; Huang S; Guo F; Xu F; Cheng P; Ye Y; Dong Y; Xiang W; Chen A
Mol Med Rep; 2016 Jan; 13(1):613-22. PubMed ID: 26648136
[TBL] [Abstract][Full Text] [Related]
12. Tumour macrophages as potential targets of bisphosphonates.
Rogers TL; Holen I
J Transl Med; 2011 Oct; 9():177. PubMed ID: 22005011
[TBL] [Abstract][Full Text] [Related]
13. Extracellular Ca(2+)-dependent enhancement of cytocidal potency of zoledronic acid in human oral cancer cells.
Inoue S; Arai N; Tomihara K; Takashina M; Hattori Y; Noguchi M
Eur J Pharmacol; 2015 Aug; 761():44-54. PubMed ID: 25934567
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid inhibits thyroid cancer stemness and metastasis by repressing M2-like tumor-associated macrophages induced Wnt/β-catenin pathway.
Lv J; Chen FK; Liu C; Liu PJ; Feng ZP; Jia L; Yang ZX; Hou F; Deng ZY
Life Sci; 2020 Sep; 256():117925. PubMed ID: 32522570
[TBL] [Abstract][Full Text] [Related]
15. Alteration of macrophage viability, differentiation, and function by bisphosphonates.
Patntirapong S; Poolgesorn M
Oral Dis; 2018 Oct; 24(7):1294-1302. PubMed ID: 29869362
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid induces apoptosis via stimulating the expressions of ERN1, TLR2, and IRF5 genes in glioma cells.
Biray Avci C; Kurt CC; Tepedelen BE; Ozalp O; Goker B; Mutlu Z; Dodurga Y; Elmas L; Gunduz C
Tumour Biol; 2016 May; 37(5):6673-9. PubMed ID: 26646564
[TBL] [Abstract][Full Text] [Related]
17. The miR-21/PTEN/Akt signaling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines.
Fragni M; Bonini SA; Bettinsoli P; Bodei S; Generali D; Bottini A; Spano PF; Memo M; Sigala S
Naunyn Schmiedebergs Arch Pharmacol; 2016 May; 389(5):529-38. PubMed ID: 26905520
[TBL] [Abstract][Full Text] [Related]
18. The tumor-educated-macrophage increase of malignancy of human pancreatic cancer is prevented by zoledronic acid.
Hiroshima Y; Maawy A; Hassanein MK; Menen R; Momiyama M; Murakami T; Miwa S; Yamamoto M; Uehara F; Yano S; Mori R; Matsuyama R; Chishima T; Tanaka K; Ichikawa Y; Bouvet M; Endo I; Hoffman RM
PLoS One; 2014; 9(8):e103382. PubMed ID: 25116261
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
20. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function.
Veltman JD; Lambers ME; van Nimwegen M; Hendriks RW; Hoogsteden HC; Aerts JG; Hegmans JP
BMC Cancer; 2010 Aug; 10():464. PubMed ID: 20804550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
